SWS: 63% of Filipinos prefer US-made vaccines

enablePagination: false
maxItemsPerPage: 10
totalITemsFound:
maxPaginationLinks: 10
maxPossiblePages:
startIndex:
endIndex:

Metro Manila (CNN Philippines, May 25) — A Social Weather Stations poll revealed that 63% of adult Filipinos prefer COVID-19 vaccines manufactured in the United States.

According to the national survey, China was chosen as the second preferred source of coronavirus shots with 19%. This was followed by Japan (13%), Australia (13%), United Kingdom (13%), Canada (12%), Russia (12%), Germany (8%), South Korea (6%), and India (3%).

Two percent chose all said countries, while 12% did not give their answer.

Per area, US-made COVID-19 shots were also most preferred, with 66% in the Visayas, 65% in Balance Luzon, 63% in Metro Manila, and 54% in Mindanao.

The same was also observed in terms of education level. Preference is highest among college graduates at 67%, followed by junior high school graduates (66%), elementary graduates (58%), and non-elementary graduates (55%).

When asked about the vaccine brand they prefer, 39% of the respondents chose China’s Sinovac Biotech, followed by US’ Pfizer-BioNTech (32%), United Kingdom’s Oxford-AstraZeneca (22%) and Johnson & Johnson (10%).

Other brands mentioned by respondents were Moderna (7%), CureVac (3%), Sinopharm (3%), Novavax (3%), Sanofi-GSK (3%), and Gamaleya (2%). Two percent, meanwhile, chose all brands, while 19% did not give an answer.

SWS also said that 76% of those who chose China also chose Sinovac, while 43% of those who preferred Pfizer and 41% of those who chose Sinovac prefer US as a vaccine source. Preference for AstraZeneca was also highest among those who chose UK as their source of vaccines, the poll noted.

Forty-four percent of respondents from the Visayas and Mindanao also said their top brand choice was Sinovac. Meanwhile, the China-made brand and Pfizer were equally preferred in Metro Manila with 37%.

Currently, the country has received over 7 million COVID-19 vaccines, most of which are Sinovac, followed by AstraZeneca, and Gamaleya. The initial 193,000 doses of Pfizer’s vaccine arrived on May 10.

The First Quarter 2021 survey was conducted from April 28 to May 2 through face-to-face interviews of 1,200 adults nationwide. The sampling error margins are ±3% for national percentages and ±6% for Balance Luzon, Metro Manila, the Visayas, and Mindanao.